Anteris Technologies

@DeviceTalks Minnesota is just around the corner! We’re pleased to share that Anteris CEO Wayne Paterson will take the stage on Monday, May 4 at 10:30 a.m. We look forward to an engaging discussion about the next generation of heart valve technology. 🔗 minnesota.devicetalks.com #DeviceTalksMinnesota #MedTech #HeartValves #TAVR #TAVI

Today on Heart Valve Disease Awareness Day, we’re joining the global effort to shine a light on a condition that affects millions—often without symptoms. Heart valve disease, including conditions like aortic stenosis, can progress silently, making awareness and early detection essential for better outcomes. In this video, our Chief Medical Officer Christopher Meduri explains aortic stenosis symptoms and treatment options. For more information on symptoms or treatment, speak with your doctor. This day is a reminder to: ✔️ Know the signs—fatigue, breathlessness, chest pain, dizziness ✔️ Encourage loved ones to get regular heart check-ups ✔️ Support continued research and innovation in cardiovascular health Anteris remains dedicated to advancing outcomes for aortic stenosis patients and increasing understanding of this serious condition. #HeartValveDiseaseAwarenessDay #HeartHealth #AorticStenosis #CardiovascularCare #HeartMonth

📢 Just published! New data presented by Dr. Pankaj Garg at EAPCI Summit 2026 and simultaneously published in European Heart Journal demonstrated that the biomimetic DurAVR® Transcatheter Heart Valve, with its native-shaped leaflet geometry, restored native-like flow in patients with severe, symptomatic aortic stenosis. The post-DurAVR® THV aortic flow was comparable to that seen in age-, sex-, and hemodynamic-matched controls without aortic valve disease. The 4D CMR study evaluated 60 patients with severe AS pre-intervention and 6-months post-DurAVR® THV and compared aortic flow and LV mass to 35 matched controls, revealing: ✅ Significant reduction in flow displacement and flow reversal ratio post-DurAVR® THV vs. severe AS ✅ Post-DurAVR THV flow displacement comparable to matched healthy controls ✅ Significant LV mass reduction post-DurAVR, with LV mass returning to levels comparable to matched healthy controls At Anteris, our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Together with our physician partners, we are working to advance valve science and outcomes for patients suffering from aortic stenosis. The currently enrolling PARADIGM Trial, with its imaging sub-study, has the potential to help uncover the clinical implications of restoring physiologic flow. Read the full paper:➡️ academic.oup.com/ehjvshd/advanc… #EAPCI26 #TAVR #TAVI #AorticStenosis #Biomimetic #LaminarFlow DurAVR® THV is intended for INVESTIGATIONAL USE ONLY. Not available for commercial use or sale worldwide. Design and performance characteristics subject to clinical investigation and regulatory review. Potential contraindications, hazards, or adverse effects subject to clinical investigation and regulatory review. These materials are intended to notify clinical investigators. CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use. EU: For Investigational use only. Not CE marked.

📢 Company Update! Anteris has completed combined $320M capital raises, including $230M from a public offering and $90M from a strategic investment from @Medtronic. These combined proceeds enable Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform the treatment of aortic stenosis. “This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator,” said Wayne Paterson, Anteris Vice Chairman and CEO. Anteris and Medtronic are aligned around the belief that reshaping the Transcatheter Aortic Valve Replacement (TAVR) market requires advancing clinical science and valve design while maintaining rigorous standards for durability, hemodynamics, and long‑term patient outcomes. Read the full press release to learn more: anteristech.com/investors/pres… #TAVR #TAVI #AorticStenosis #PARADIGMtrial #MedTech

Hear perspectives from Prof. Ole De Backer and Prof. Nicolas Van Mieghem about the recent DurAVR® THV data and the PARADIGM Trial in this 2-part discussion series. ➡️ Part 1 highlights the PARADIGM trial—the first all-comers, head-to-head TAVI trial and the first TAVI trial designed to evaluate post-procedure blood flow patterns using cardiac MRI. With participation from 80 centers across the US, Canada, and Europe, recent FDA IDE approval, and first enrollments already completed in Denmark in October, the PARADIGM Trial is expected to enroll quickly, and the data gathered will be used to support future commercial approval of the DurAVR® valve for patients across all risk categories. 📽️ Watch Part 1: youtu.be/55R3Br-Ws6w?si… ➡️ Part 2 focuses on Prof. De Backer’s presentation of 30-day outcomes from 100 small annuli DurAVR® THV patients, providing early insights into clinical performance. DurAVR® THV demonstrated a favorable hemodynamic profile at 30 days, including 97% freedom from moderate or greater patient-prosthesis mismatch (PPM).(1) 📽️ Watch Part 2: youtu.be/UU6uhlsryRw?si… (1) De Backer O. Oral Presentation at: PCR London Valves; Nov 2025; London, UK. #TAVI #TAVR #AorticStenosis #PARADIGMtrial #MovingtheConversationForward DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: For clinical investigations only. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

💥Just presented at PCR London Valves, with simultaneous EuroIntervention publication! Professor Ole De Backer shared the latest DurAVR® THV clinical data from 100 small annuli patients at 30 days post-implantation. Here are the highlights: ✅ DurAVR® THV delivered a favorable hemodynamic profile with a large EOA of 2.2 ± 0.3 cm2 and a single digit mean pressure gradient (MPG) of 8.2 ± 3.1 mmHg. At 30 days, clinical safety outcomes were positive with no valve-related mortality and no moderate or severe paravalvular leak (PVL). ✅ 97% freedom from moderate or greater prosthesis-patient mismatch* "The DurAVR® THV demonstrated high rates of technical and device success with encouraging 30-day hemodynamic outcomes, including very low PPM in small annuli patients. These results reflect a unique balance of balloon-expandable benefits characterised by high device success and low pacemaker rates, combined with a hemodynamic profile typically associated with self-expanding platforms," said Prof. De Backer, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Read the full press release: anteristech.com/investors/pres… #PCRLV #TAVI #TAVR #AorticStenosis #MovingtheConversationForward *Prosthesis‐patient mismatch (PPM) happens when a prosthetic valve, after being implanted, doesn't have a large enough opening (EOA) to accommodate the patient's blood flow needs, based on their body size. The result is higher than expected gradients. PPM affects a significant proportion of transcatheter aortic valve (TAVR) patients, particularly patients with a small aortic annulus and has been associated with impaired long-term survival following surgical aortic valve replacement (SAVR). **As defined in VARC-3. The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

#TeamAnteris shaping the future of structural heart disease care since 1998

Anteris is proud to be part of the community revolutionizing total disease management in aortic stenosis by reshaping paradigms

Excited to kick off at PCR London Valves! Today, we’re presenting the latest data from DurAVR® THV, adding to the body of evidence, and reshaping the future treatment of aortic stenosis by shifting the paradigm.

We are excited to share new clinical data at PCR London Valves next week! On Sunday, November 16 Professor Ole De Backer will present data from 100 DurAVR® THV clinical cases in small annuli. Not attending? Sign up here for clinical data updates: bit.ly/3Jtyafx #TAVI #TAVR #aorticstenosis #PCRLV The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

At Anteris, our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. We’ve partnered with the Minneapolis Heart Institute Foundation to conduct important research into how to better diagnose and treat aortic stenosis. At TCT, Dr. Miho Fukui presented a new concept that uses a percentage in aortic valve area (AVA) reduction for determining disease severity, rather than applying the same AVA cutoffs to all patients despite different valve sizes. View her full TCT presentation to learn more: anteristech.com/news/tct-2025-… #TCT2025 #TAVI #TAVR #aorticstenosis #clinicalresearch

Anteris at TCT: PARADIGM Trial Momentum! At the TCT Conference in San Francisco, Anteris brought together global leaders for a captivating PARADIGM Trial Investigator Meeting. Vice Chairman and CEO Wayne Paterson shared our journey to redefine valve replacement therapy. Prof. Ole De Backer shared his experience with the DurAVR® THV System and the excitement about the trial approval and first cases in Denmark. Thank you to all investigators and partners shaping the future of aortic stenosis care! #TCT2025 #PARADIGMtrial #TAVI #TAVR #AorticStenosis The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

📢 PARADIGM Trial Announcement! Anteris has received US FDA approval to launch the PARADIGM Trial for the DurAVR® Transcatheter Heart Valve (THV). The head-to-head global Investigational Device Exemption (IDE) trial will evaluate the DurAVR® Transcatheter Heart Valve (THV) compared to commercially available THV in patients with severe calcific aortic stenosis. “We are extremely pleased to receive FDA approval for the PARADIGM Trial, which allows us to commence patient recruitment in the United States**. This milestone, together with the recent launch of the trial and first patients treated in Denmark, represents a significant achievement and a key step forward in advancing this life-saving technology worldwide for patients living with aortic stenosis, a debilitating and progressive condition. - Vice Chairman and CEO, Wayne Paterson. Read full press release: anteristech.com/investors/pres… #PARADIGMtrial #clinicaltrial #aorticstenosis #TAVR #TAVI **Subject to Institutional Review Board (IRB) approval The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

Hot off the press from TCT! We are excited to announce the first patient has been enrolled in the global PARADIGM Trial! Yesterday Dr. Rishi Puri presented this important update at TCT, along with an update on DurAVR® THV clinical evidence from the EMBARK and EFS studies. The procedure was performed by Professor Ole De Backer at Rigshospitalet in Copenhagen, Denmark. “We are proud to be the first enrolling center for this important trial,” said Professor De Backer. “Our initial experience with the DurAVR® THV System has been very positive, and we look forward to providing definitive comparative evidence which could transform patient care.” Read the full announcement: anteristech.com/investors/pres… #PARADIGMtrial #TAVI #TAVR #aorticstenosis #TCT2025 The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

We are excited to share the latest clinical data at TCT next week! On Monday, October 27 Dr. Rishi Puri will present data from DurAVR® THV clinical experience. Not attending? Sign up here for clinical data updates: bit.ly/49iBIvo #TAVI #TAVR #aorticstenosis #TCT2025 The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

The Paradigm Shift Starts Now! Last week, we received regulatory clearance to commence the pivotal trial for the first-in-class biomimetic DurAVR® valve. The PARADIGM Trial is the first head-to-head TAVR trial of its kind. The trial will move beyond conventional endpoints of safety, efficacy, and hemodynamic performance, aiming to also uncover the clinical impact of restoring physiologic flow patterns. Listen to the video to hear perspectives from several global TAVR leaders. This global pivotal trial has the potential to shift the treatment paradigm for aortic stenosis and redefine what is possible with TAVR. Learn more ➡️ bit.ly/47gDESr #PARADIGMtrial #StructuralHeart #AorticStenosis #TAVR #TAVI The DurAVR® THV System is an investigational device. The DurAVR® THV System is not available for commercial sale.

The Paradigm Shift Starts Now! We are proud to announce a major milestone: regulatory clearance to commence the global PARADIGM Trial for our DurAVR® Transcatheter Heart Valve (THV). This pivotal study marks the beginning of a new era in the treatment of severe aortic stenosis, bringing cutting-edge, biomimetic valve technology to patients worldwide. “The PARADIGM Trial enables us to bring promising new technology to patients across all surgical risk groups, building on the growing body of evidence supporting the DurAVR® THV’s favorable hemodynamic performance. We look forward to contributing meaningful data which could support both PMA* and CE Mark approvals,” said Dr. Michael Reardon and Professor Stephan Windecker, Study Co-Chairs of the global PARADIGM Trial. This achievement reflects the dedication of our talented Anteris team, visionary physician partners, and the trust of our patients and shareholders. Together, we are advancing the future of structural heart therapy. Learn more about the PARADIGM Trial and how DurAVR® THV is setting a new standard for physiological heart valve performance: anteristech.com/investors/pres… #PARADIGMtrial #StructuralHeart #AorticStenosis #TAVR #TAVI *A Premarket Approval (PMA) application requires a high level of clinical evidence to demonstrate reasonable assurance of safety and effectiveness for the intended use. Randomized controlled trials are generally considered Level 1 evidence, the highest level for determining the effectiveness of interventions in evidence-based medicine given RCTs minimize bias and allow a clear comparison between treatment groups. DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.
EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

New publication in EuroIntervention just released! We are pleased to share the results of a bench study on the biomimetic DurAVR® Transcatheter Heart Valve (THV). The bench study evaluated the hydrodynamic performance of the DurAVR® valve compared to commercially available THV in three key deployment scenarios: native TAVI, valve-in-valve (VIV), and redo-TAVI. These bench study findings corroborate the clinical evidence collected to date in 130 patients, supporting excellent hemodynamics across a wide range of deployment configurations due to the valve’s unique single-piece, native-shaped biomimetic design. Study Highlights: ➡️ Native TAVI: The DurAVR® valve demonstrated superior effective orifice area (EOA ≥ 3 cm²) and low mean gradients (<6 mmHg) in the study. ➡️ Valve-in-Valve: The DurAVR® valve exhibited larger EOAs and lower MGs than the comparator THVs included in the study across valve sizes, with the greatest difference seen in smaller surgical valves. ➡️ Redo-TAVI: The DurAVR® valve exhibited larger EOA and lower gradients than all other THVs tested in the study. ➡️ Across all scenarios, the DurAVR® valve showed mild-to-no pinwheeling, indicating stable leaflet dynamics. 📓 Read the full publication here: eurointervention.pcronline.com/article/duravr… #TAVI #TAVR #StructuralHeart #HeartValve #ViV #RedoTAVI #AorticStenosis @EuroInterventio DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

How do flow patterns impact the cardiovascular system? Does valve design impact flow patterns? In this new whitepaper, we review the pathophysiology of aortic stenosis—including upstream and downstream consequences of turbulent flow—and offer hypotheses around the impacts of TAVR design on flow patterns and disease regression. 📖Click to read ➡️anteristech.com/news/the-impor… #FlowDynamics #TAVI #TAVR #AorticStenosis #MovingtheConversationForward